Skip to main content
. 2023 May 18;257:115503. doi: 10.1016/j.ejmech.2023.115503

Fig. 3.

Fig. 3

Discovery of the orally available SARS-CoV-2 RdRp covalent inhibitor azvudine. (a) Important milestones in azvudine discovery from NM-107 to the first-in-class HIV and SARS-CoV-2 dual inhibitor azvudine. (b) Medicinal chemistry efforts led to discovery of the oral RdRp inhibitor azvudine. (c) Proposed mechanism of action of the prodrug azvudine against SARS-CoV-2. (d) Metabolic pathway of azvudine. (e) Structure of SARS-CoV-2 RNA with a cytosine subunit. (f) A diagram showing the SARS-CoV-2 RNA replication process blocked by the active metabolite azvudine triphosphate through formation of a covalent bond.